Patient
P2B-062
completed Phase IIA Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma · Sarcoma Oncology Center (Santa Monica, CA) (Dr. Reyes)
consented 2012-12-19
Adverse events
8
Serious AEs
3
Open data queries
5
Luna dropout signal
—
not on Luna
Adverse events 8
Grade 3 atrial fibrillation with onset in cycle 6 (2013-05-16); serious (hospitalization); assessed as not related to study drug (not related); resolved 2013-05-19.
Grade 3 pneumothorax with onset in cycle 6 (2013-05-13); serious (hospitalization); assessed as not related to study drug (not related); resolved 2013-05-25; action: drug interrupted.
Grade 2 fatigue with onset in cycle 5 (2013-04-27); assessed as not related to study drug (unlikely); resolved 2013-05-26.
Grade 1 diarrhoea with onset in cycle 5 (2013-04-23); assessed as not related to study drug (not related); resolved 2013-04-28.
Grade 2 neutropenia with onset in cycle 2 (2013-02-17); assessed as related to study drug (probable); resolved 2013-02-24.
Grade 1 alopecia with onset in cycle 1 (2013-01-23); assessed as related to study drug (probable); not resolved at last follow-up.
Grade 2 diarrhoea with onset in cycle 1 (2013-01-19); serious (hospitalization); assessed as not related to study drug (not related); resolved 2013-01-21.
Grade 2 leukopenia with onset in cycle 1 (2013-01-17); assessed as related to study drug (probable); resolved 2013-01-26.
Data queries 5
Visit Cycle 6 Day 1: infusion (last planned cycle) (V7) for P2B-062 occurred on 2013-05-04, 10 d late against planned day 106 (2013-04-24 ± 3 d, anchored on first dose 2013-01-09). Confirm the visit date or record a protocol deviation.
Visit Cycle 5 Day 1: infusion; week-12 CT/MRI and ECHO/MUGA before dosing (V6) for P2B-062 occurred on 2013-04-13, 10 d late against planned day 85 (2013-04-03 ± 3 d, anchored on first dose 2013-01-09). Confirm the visit date or record a protocol deviation.
Visit Cycle 4 Day 1: infusion (V5) for P2B-062 occurred on 2013-03-23, 10 d late against planned day 64 (2013-03-13 ± 3 d, anchored on first dose 2013-01-09). Confirm the visit date or record a protocol deviation.
Visit Cycle 3 Day 1: infusion; week-6 CT/MRI and ECHO/MUGA before dosing (V4) for P2B-062 occurred on 2013-03-03, 11 d late against planned day 43 (2013-02-20 ± 3 d, anchored on first dose 2013-01-09). Confirm the visit date or record a protocol deviation.
Visit Cycle 2 Day 1: infusion (V3) for P2B-062 occurred on 2013-02-11, 12 d late against planned day 22 (2013-01-30 ± 3 d, anchored on first dose 2013-01-09). Confirm the visit date or record a protocol deviation.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.